[Philadelphia chromosome-positive acute lymphoblastic leukemia with monosomy 7 successfully treated with intermediate- and high-dose ara-C].
A 52-year-old man was admitted for treatment of acute lymphoblastic leukemia (ALL). The bone marrow was hypercellular with 67.2% blasts, which were negative for peroxidase, and expressed CD13, CD33, CD34, CD10 and CD7. Cytogenetic and molecular studies revealed t(9;22) and -7(Ph/-7) with major BCR/ABL rearrangement. The patient was treated with the L-AdVP regimen, but failed to achieve complete remission (CR). He then received two courses of chemotherapy consisting of intermediate- and high-dose cytarabine (ara-C), resulting in CR. This case suggests that Ph/-7 ALL with major BCR/ABL gene rearrangement showing coexpression of myeloid antigens may be sensitive to intermediate- and high-dose ara-C.
Hatsuse
M
M
Second Department of Medicine, Kyoto Prefectural University of Medicine.
Shimazaki
C
C
Tsubakimoto
Y
Y
Ochiai
N
N
Okano
A
A
Ashihara
E
E
Inaba
T
T
Fujita
N
N
Nakagawa
M
M
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D002897:Chromosomes, Human, Pair 7 / Q000235:genetics*; D003561:Cytarabine / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009006:Monosomy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics*
D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine